Close
Smartlab Europe
Achema middle east

Ranbaxy launches cholesterol reducing drug in Australia

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Teva, Royalty Pharma $500M Deal to Advance Autoimmune Drug

Teva Pharmaceutical Industries and Royalty Pharma have signed a...

Pierre Fabre, Iktos Launch AI-Driven Oncology Drug Discovery

An integrated partnership has been formed between Pierre Fabre...

Revvity and Lilly Expand Lilly TuneLab Access via Signals

Revvity, Inc. announced a collaboration with Eli Lilly and...
- Advertisement -

Ranbaxy Australia, a subsidiary of Ranbaxy Laboratories, has introduced Atorvastatin 10mg, 20mg, 40mg and 80mg tablets after receiving approval from Therapeutic Goods Administration (TGA) in Australia.

The product is launched under the brand name Trovas in bottles and blister packs, through retail pharmacy chains. Atorvastatin, a cholesterol reducing drug, is the most prescribed statin in Australia and represents the largest patent expiry opportunity ever, in the Australian pharmaceutical market, the company said. Ranbaxy Australia managing director Alex Evans said Ranbaxy is privileged to be the first generic pany in Australia to introduce Atorvastatin under the brand name, Trovas.

Latest stories

Related stories

Teva, Royalty Pharma $500M Deal to Advance Autoimmune Drug

Teva Pharmaceutical Industries and Royalty Pharma have signed a...

Pierre Fabre, Iktos Launch AI-Driven Oncology Drug Discovery

An integrated partnership has been formed between Pierre Fabre...

Revvity and Lilly Expand Lilly TuneLab Access via Signals

Revvity, Inc. announced a collaboration with Eli Lilly and...

Amgen Eyeing Preclinical Blood Cancer Program to Its Skills

Amgen is going ahead and adding Dark Blue to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »